Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma » Lymphoma, Non-Hodgkin
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin
Description
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. MeSH
Hierarchy View
Subtype Terms (5)
Lymphoma, B-Cell
300 drugs (118 approved, 182 experimental)
Lymphoma, Follicular
339 drugs (143 approved, 196 experimental)
Lymphoma, Large-Cell, Immunoblastic
282 drugs (145 approved, 137 experimental)
Lymphoma, Mantle-Cell
319 drugs (133 approved, 186 experimental)
Lymphoma, T-Cell
243 drugs (115 approved, 128 experimental)
Approved Indicated Drugs (13)
Phase 4 Indicated Drugs (26)
Phase 3 Indicated Drugs (76)
allogeneic hematopoietic stem cells (Hemacord)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous hematopoietic stem cells
autologous mononuclear stem cell
autologous umbilical cord blood
Phase 2 Indicated Drugs (199)
allogeneic natural killer cells
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous effector lymphocytes expanded ex-vivo
autologous immunoglobulin idiotype-klh conjugate vaccine
autologous mesenchymal stem cells
axicabtagene ciloleucel (Yescarta)
bone marrow derived mesenchymal stem cells
car-t targeted cd19/cd20/cd22/cd30
erwinia asparaginase (Erwinaze)
haplo-identical hematopoietic stem cells
human fecal microbiota (Reybota)
hyaluronidase (human recombinant) (Hylenex)
lisocabtagene maraleucel (Breyanzi)
lmp2a-loaded conventional dc vaccine
multi-peptide cmv-modified vaccinia ankara vaccine
Phase 1 Indicated Drugs (307)
allogeneic gamma-delta t cells
anti-cd19-car cmv-specific t-lymphocytes
anti-cd19/cd20/cd22 car t-cells
anti-cd20 b9e9 scfv-streptavidin fusion protein
autologous car.cd30 ebv specific-ctls
autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes
autologous cd34+ cells transduced withpsrs11.efs.il2rg.pre
autologous ebv specific cytotoxic t lymphocytes
autologous natural killer cells
barf1-specific cytotoxic t-lymphocytes
c46/ccr5/p140k lentiviral vector-transduced autologous hspcs
cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes
cd19/cd20 bispecific car-t cells
cd19-targeted non-viral pd1 site-specific integrated car-t cell injection
cd34-tk75 transduced donor lymphocytes
in111 anti-cd45 monoclonal antibody bc8
lmp-specific cytotoxic t-lymphocytes
lvsh5/c46 (cal-1) transduced cd34+ hematopoietic stem cells
n-(4-hydroxyphenyl)all-trans retinamide
ny-eso-1, magea4, prame, survivin and ssx - specific t cells
Organization Involved with Phase 4 Indications (27)
Organization Involved with Phase 3 Indications (123)
Australasian Leukaemia and Lymphoma Group
Blood and Marrow Transplant Clinical Trials Network
British Columbia Cancer Agency
Cancer and Leukemia Group B (CALGB)
Center for International Blood and Marrow Transplant Research
City of Hope National Medical Center
German High-Grade Non-Hodgkin's Lymphoma Study Group
German Low Grade Lymphoma Study Group
Gruppo Italiano Studio Linfomi
Hematology Oncology Associates of the Palm Beaches
Hoosier Cancer Research Network
HOVON - Dutch Haemato-Oncology Association
Justus Liebig University Giessen
National Cancer Institute (NCI)
National Center for Research Resources (NCRR)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Russian Academy of Medical Sciences
Scotland and Newcastle Lymphoma Group
Shandong Lanjin Pharmaceuticals Co.,Ltd
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
Technical University of Dresden
Organization Involved with Phase 2 Indications (330)
Academic and Community Cancer Research United
American Society of Clinical Oncology
Arbeitsgemeinschaft medikamentoese Tumortherapie
Azienda Ospedaliera San Giovanni Battista
Badalona Hospital Germans Trias i Pujol
Bambino Gesù Hospital and Research Institute
Beijing Immunochina Medical Science & Technology Co., Ltd.
Boryung Pharmaceutical Company
Case Western Reserve University
Centro di Riferimento Oncologico - Aviano
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Centro Medico Nacional La Raza, IMSS
Children's Cancer Group, China
Children's Hospital Los Angeles
Clinica Universidad de Navarra
Consortium for Improving Survival of Lymphoma
Damon Runyon Cancer Research Foundation
Doris Duke Charitable Foundation
Dynavax Technologies Corporation
Fondazione Italiana Diabete Onlus
Franklin Square Hospital Center
French Innovative Leukemia Organisation
French National Agency for Research on AIDS and Viral Hepatitis
Fundación Leucemia y Linfoma, Spain
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Henan University of Traditional Chinese Medicine
Hôpital Maisonneuve Rosemont, Montréal, QC, Canada
Hospital Fundación de Alcorcon
Hospital Universitario Arnau de Vilanova de Lleida
Hospital Universitario Central de Asturias
Hospital Universitario Puerta del Mar
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Innovative Therapies For Children with Cancer Consortium
International Extranodal Lymphoma Study Group
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Katholieke Universiteit Leuven
Lymphoma Disease Committee of TCOG
Memorial Sloan-Kettering Cancer Center
National Cheng Kung University
National Institute on Aging (NIA)
National University of Singapore
New Mexico Cancer Care Alliance
North Central Cancer Treatment Group
Oregon Health and Science University
Ospedale S. Giovanni Bellinzona
Prologue Research International
Royal Marsden Hospital NHS Trust
Shanghai Bioray Laboratory Inc.
Shanghai Ming Ju Biotechnology Co., Ltd.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Shanghai YingLi Pharmaceutical Co. Ltd.
Shijiazhuang Pharma Group (CSPC)
Spanish National Health System
St. John Hospital and Medical Center, Van Elslander Cancer Center
TaiGen Biotechnology Co., Ltd.
Technical University of Munich
The Alvin and Lois Lapidus Cancer Institute
The First People's Hospital of Changzhou
The Leukemia and Lymphoma Society
The Lymphoma Academic Research Organisation
The Scientific and Technological Research Council of Turkey
The University of Texas, Dallas
The Wayne D. Kuni and Joan E. Kuni Foundation
Translational Research Institute for Metabolism and Diabetes, Florida
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
Universidad Autonoma de Nuevo Leon
Universidad Complutense de Madrid
University of Alabama, Birmingham
University of California, Davis
University of California, San Diego
University of Colorado, Denver
University of Illinois at Chicago
University of Las Palmas de Gran Canaria
University of Medicine and Dentistry of New Jersey
University of Roma La Sapienza
University of Southern California
University of Southern Denmark
Virginia Commonwealth University
Vita-Salute University of Milano. Italy
Organization Involved with Phase 1 Indications (112)
Aeon Therapeutics (Shanghai) Co., Ltd.
Beijing GD Initiative Cell Therapy Technology Co.，Ltd.
Cellular Biomedicine Group Ltd.
CLL Global Research Foundation
Cook Children's Medical Center
Fundación Centro Oncológico de Integración Regional - COIR.
Hebei Senlang Biotechnology Inc., Ltd.
Hospital Privado De Santa Clara De Asis
Hospital Regional De Concepción
Medical University of South Carolina
Nanjing Sanhome Pharmaceutical, Co., Ltd.
National Comprehensive Cancer Network
Organization Involved with Other Experimental Indications (11)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
